CRISPR-Cas13 RNA Editing: Why Targeting RNA Instead of DNA Opens New Medical Possibilities

You have probably heard of CRISPR-Cas9 — the gene-editing tool that cuts DNA and has been described, with some justification, as one of the most significant biological discoveries in decades. But there is a quieter sibling technology that has been advancing alongside it, and it may turn out to be medically more useful in a wider range of situations.

*CRISPR-Cas13 targets RNA rather than DNA.* And that difference — which might sound like a technicality — changes almost everything about what you can do with it and when you can safely use it.

## What's the actual difference between DNA and RNA editing?

Think about the genome this way: DNA is the master blueprint, locked away in the cell nucleus, consulted only when something needs to be made. RNA is the working copy — a temporary transcript that is produced when a gene is active, carries the instructions out of the nucleus, and gets translated into protein at the ribosome. DNA is permanent and heritable; RNA is transient and specific to what the cell is currently doing.

CRISPR-Cas9 edits DNA. It makes a permanent cut in the genome — a change that is heritable if it happens in the germline, and that is present in every descendant cell if it happens during development. This permanence is both its power and its risk. If the edit is wrong — if Cas9 cuts in the wrong place, or if the correction is imprecise — the error is also permanent. This is why the regulatory pathway for DNA-editing therapies is so cautious, and why the debate about germline editing (editing embryos) is so fraught.

**Cas13 works differently.** Cas13 binds to and destroys specific RNA sequences. Because RNA is transient — it is constantly being produced and degraded — a Cas13 intervention is, in principle, reversible. Stop delivering the Cas13 system, and the cell eventually returns to its normal RNA profile. You are not rewriting the blueprint. You are intercepting messages.

> 🔬 **Quick experiment:** Consider what this means practically. If you have a disease caused by a mutant protein — say, a misfolded tau protein that accumulates in Alzheimer's disease — Cas13 could target the RNA that codes for that protein before it is ever made. No protein, no accumulation.

## So why haven't we been using Cas13 all along?

Here's the weird part. Cas13 was actually identified before its usefulness for gene editing was fully appreciated. The original CRISPR systems in bacteria were known to target both DNA and RNA. But Cas9's DNA-editing capability attracted so much research attention so quickly that RNA-targeting systems received much less initial investment.

The Sternberg and Zhang labs at MIT and Columbia, along with others, began characterising Cas13 in earnest around 2016–2017. What they found was a family of enzymes — Cas13a, Cas13b, Cas13c, Cas13d — each with distinct properties in terms of RNA-cleavage efficiency and delivery requirements. Cas13d, also called CasRx, became a particular focus because of its smaller size, which matters enormously for delivery: smaller tools fit more easily into viral vectors like AAV (adeno-associated virus) that are used to deliver gene-editing machinery into cells.

The challenge was, and partially remains, specificity. When you knock out an RNA sequence, you need to be sure you are hitting only the target. Cas13 has a property called "collateral cleavage" — when it finds and cuts its target RNA, it can also begin non-specifically degrading nearby RNAs. In a test tube, this is actually useful (it's the basis of the SHERLOCK diagnostic platform). Inside a living cell, it is a potential source of off-target effects that researchers have spent years working to minimise.

## What Cas13 can do that Cas9 cannot

There are several clinically important situations where editing RNA is specifically advantageous.

**Neurological disease.** Neurons — brain cells — almost never divide. This means that once a permanent DNA edit is made in a neuron, it is there for life. The stakes of a DNA error are especially high. Cas13, by contrast, offers a more cautious approach: deliver it, reduce the expression of a harmful protein, and if something goes wrong, stop delivery and let the effect wear off. For conditions like ALS, frontotemporal dementia, and Huntington's disease — all driven by toxic proteins encoded in specific RNAs — this property is clinically valuable.

**Infectious disease.** Viruses replicate through RNA (RNA viruses like influenza, SARS-CoV-2, and many others). Cas13 can target viral RNAs directly, potentially disrupting replication. The Broad Institute's CARVER platform (Cas13-Assisted Restriction of Viral Expression and Readout) demonstrated in 2019 that Cas13 could reduce influenza replication in cell culture. The timeline from lab demonstration to clinical use is long, but the principle is established.

**Splice modulation.** Many genetic diseases arise not from mutations in the protein-coding sequence itself, but from mutations that disrupt how RNA is spliced — how pieces of the gene are joined together. RNA-targeting tools can interfere with specific splice sites, potentially correcting the processing error. This is a different mechanism than current antisense oligonucleotide approaches and may prove more versatile.

> 🔬 **Quick experiment:** Think about it this way. If DNA editing is surgery — precise but permanent — RNA editing is more like pharmacology: targeted, dose-adjustable, and reversible. For diseases where you need to modulate rather than eliminate a gene's function, that matters.

## Where research stands in 2026

The field has moved substantially in the last three years. Several academic groups have demonstrated Cas13 efficacy in animal models of neurological disease, particularly for ALS-associated mutations in the SOD1 and TDP-43 genes. Delivery remains the central problem: getting Cas13 constructs into the right cells, in the right tissues, in sufficient quantity for therapeutic effect.

The intellectual property landscape is complicated — as it has been throughout the CRISPR field — but several biotech companies have built Cas13-focused platforms, including Locanabio (neurological diseases), ProQR Therapeutics (RNA-targeting approaches for retinal disease), and Wave Life Sciences (antisense and CRISPR RNA modulation).

Clinical trials in humans remain at an early stage. The leap from cell culture and mouse models to human use involves not only efficacy questions but manufacturing challenges: producing consistent, high-quality Cas13 constructs at scale, demonstrating safety in larger animals, and navigating regulatory frameworks that are still being developed for RNA-editing therapies.

## What we still don't fully understand

The collateral cleavage problem has been significantly reduced through protein engineering — modified versions of Cas13 with attenuated non-specific activity. Whether these modifications are sufficient for long-term clinical safety in humans is not yet established.

The immunogenicity of Cas13 is also an open question. Like Cas9, Cas13 is a bacterial protein, and the human immune system may recognize it as foreign, potentially limiting repeat dosing. This is a problem the entire field of gene editing has not fully solved.

*Here's the weird part — the more we understand about RNA biology, the more it becomes clear that the cell's management of its own RNA is vastly more complex than we appreciated a decade ago. Cas13 is a tool designed to intervene in a system we are still in the process of fully mapping.*

CRISPR-Cas13 RNA Editing: Why Targeting RNA Instead of DNA Opens New Medical Possibilities

// COMMENTS

ON THIS PAGE